ClinicalTrials.gg

Stomatitis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 306 studies for Stomatitis across more than 10 countries. 75 are recruiting or about to start. 208 of them are mainly about Stomatitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 3 narrower conditions too, such as Stomatitis, Aphthous: 428 studies, 99 open.

Status

Completed
155
Recruiting
47
Status unknown
40
Not yet recruiting
23
Terminated
20
Withdrawn
8

Phase

Phase 2
101
Phase 3
50
Phase 1
24
Phase 4
16
Early Phase 1
4

Where

United States
80
China
31
Egypt
28
France
17
Italy
17
Turkey
16

Who develops what

Add Stomatitis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 0 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CisplatinRecent, limited
Evidence
  • NCT05966194 · EpicentRx, Inc. · Phase 2 · live · background · “Cisplatin for injection 100 mg/m2” · registered Jul 2023
  • NCT04529850 · Galera Therapeutics, Inc. · Phase 2 · background · “Cisplatin” · registered Aug 2020
  • NCT03515538 · EpicentRx, Inc. · Phase 2 · background · “Cisplatin for injection” · registered Apr 2018
  • NCT02508389 · Galera Therapeutics, Inc. · Phase 2 · background · “Cisplatin” · registered Jul 2015
  • NCT00101582 · Swedish Orphan Biovitrum · Phase 3 · background · “cisplatin chemotherapy” · registered Jan 2005
Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed11 study
Dexamethasone MouthwashRecent, limited
Evidence
  • NCT07357597 · AstraZeneca · Phase 4 · live · background · “Dexamethasone mouthwash” · registered Jan 2026
—11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 23 Dec 2026 est.BupiZenge 25 mg · OncoZenge AB · Phase 3 named, not the main aimNCT07672236 A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. — primary endpoint: Total pain reduction in oral cavity pain over 3 hours after taking study treatment on the last day of radiotherapy · 150 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Stomatitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

31studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 47 Stomatitis studies recruiting now, 21 (45%) set no upper age limit and 22 (47%) stop at 75 or younger. 10 (21%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (11%) take healthy volunteers.

Recruiting studies that take each age, of 47
AgeWomenMen
108 (17%)8 (17%)
1841 (87%)41 (87%)
3040 (85%)40 (85%)
4040 (85%)40 (85%)
5040 (85%)40 (85%)
6540 (85%)40 (85%)
7529 (62%)29 (62%)
8522 (47%)22 (47%)

Across all 306 studies, recruiting or not: 34% stop at 75 or younger and 21% at 65; 21% take children; 1% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Stomatitis studies take

Of 39 phase 2 interventional studies under Stomatitis, half reached primary completion within 35 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 235 mo10–48 · 39 studies——
Phase 334 mo21–47 · 20 studies——
Interventional, no phase14 mo10–32 · 73 studies—14 mo11–57 · 65 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 306. Browse all 306 → or search them.